Are Analysts Expecting A Better 2020 For Elevation Oncology Inc (ELEV)?

Elevation Oncology Inc (ELEV) concluded trading on Thursday at a closing price of $5.13, with 0.44 million shares of worth about $2.25 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 662.26% during that period and on March 28, 2024 the price saw a gain of about 2.40%. Currently the company’s common shares owned by public are about 42.42M shares, out of which, 39.81M shares are available for trading.

Stock saw a price change of 13.75% in past 5 days and over the past one month there was a price change of 33.25%. Year-to-date (YTD), ELEV shares are showing a performance of 855.31% which increased to 170.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.36 but also hit the highest price of $5.89 during that period. The average intraday trading volume for Elevation Oncology Inc shares is 3.08 million. The stock is currently trading 13.58% above its 20-day simple moving average (SMA20), while that difference is up 45.45% for SMA50 and it goes to 230.27% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Elevation Oncology Inc (NASDAQ: ELEV) currently have 42.42M outstanding shares and institutions hold larger chunk of about 66.17% of that.

The stock has a current market capitalization of $249.57M and its 3Y-monthly beta is at 1.35. It has posted earnings per share of -$1.53 in the same period. It has Quick Ratio of 21.22 while making debt-to-equity ratio of 0.55. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ELEV, volatility over the week remained 9.25% while standing at 12.10% over the month.

Analysts are in expectations that Elevation Oncology Inc (ELEV) stock would likely to be making an EPS of -$0.2 in the current quarter, while forecast for next quarter EPS is -$0.21 and it is -$0.89 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.23 which is -$0.18 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.72 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 36.27% while it is estimated to decrease by -3.98% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JMP Securities on March 01, 2024 offering a Mkt outperform rating for the stock and assigned a target price of $7 to it. Coverage by SVB Securities stated Elevation Oncology Inc (ELEV) stock as an Outperform in their note to investors on May 30, 2023, suggesting a price target of $8 for the stock.

Most Popular

Related Posts